CorMedix (CRMD) News Today

CorMedix logo
$4.67 -0.15 (-3.11%)
Closing price 11/17/2026 04:00 PM Eastern
Extended Trading
$4.74 +0.07 (+1.50%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Why Is CorMedix Down Today?

CorMedix Inc. (NASDAQ: CRMD) faces mixed signals: a sizeable CEO share purchase and generally favorable analyst ratings are countered by lower earnings forecasts and a new sell rating. The forecast cuts and recent quarterly EPS miss may be weighing on sentiment as the stock trades near its 12-month low.

  • Positive Sentiment: CEO Joseph Todisco bought 80,000 shares for about $391,200 at an average price of $4.89, increasing his stake by 10.33%. Insider buying can signal confidence in the company. Article: CorMedix CEO Acquires 80,000 Shares
  • Positive Sentiment: Analyst sentiment remains broadly supportive: eight analysts rate CRMD Buy and two Hold, with a reported average price target of $15.22. Oppenheimer maintained an Outperform rating, though it lowered its target to $13.
  • Negative Sentiment: HC Wainwright cut its EPS forecasts across several years: Q4 2026 to a loss of $0.13 from a loss of $0.08; FY2026 to $0.38 from $0.54; FY2029 to $0.73 from $1.23; and FY2030 to $0.97 from $1.71. These reductions suggest a weaker earnings outlook.
  • Negative Sentiment: Wall Street Zen downgraded CorMedix to Sell, adding to the cautious signals. Article: CorMedix Cut to Sell at Wall Street Zen
  • Negative Sentiment: In its latest reported quarter, CorMedix missed consensus EPS expectations, posting a $0.19 loss per share versus the expected $0.12 loss, although revenue exceeded estimates.
Posted 8h agoAI Generated. May Contain Errors.

CorMedix Latest News

FY2026 EPS Estimates for CorMedix Decreased by HC Wainwright
CorMedix (NASDAQ:CRMD) CEO Acquires 80,000 Shares of Stock
CorMedix (NASDAQ:CRMD) Cut to Sell at Wall Street Zen
CorMedix's (CRMD) "Outperform" Rating Reiterated at Oppenheimer
CorMedix Inc. (CRMD) Q3 2026 Earnings Call Transcript
CorMedix (CRMD) Q3 2026 Earnings Call Transcript
What CorMedix (CRMD) Said on Its Q3 Earnings Call
CorMedix (CRMD) Set to Release Earnings on Thursday
CorMedix stock gains as Heron deal adds four products
CorMedix (CRMD) Set to Announce Earnings on Wednesday
CorMedix (NASDAQ:CRMD) Shares Down 8.3% - What's Next?
Actinium Pharmaceuticals Names Matt David CFO
CorMedix (CRMD) Q2 2026 Earnings Call Transcript
CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript
Today's Stocks in the News

CorMedix Media Mentions By Week

CorMedix Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

CRMD
News Sentiment
▼
0.30

0.56
▲
Average
Healthcare
News Sentiment

CorMedix News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

CRMD Articles
This Week
▼
23

5
▲
CRMD Articles
Average Week

CorMedix Trends on MarketBeat

This week vs. last week
New Followers
3
+50%
Searches
2
Page Views
1,786
-18%
Get CorMedix News Delivered to You Automatically

Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Related Companies and Tools


MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for CorMedix dated 11/17/2026.
From Our Partners